Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia
- 201 Downloads
Uncontrolled proliferation is a defining feature of the malignant phenotype. Ki67 is a marker for proliferating cells and is overexpressed in many breast cancers. Atypical hyperplasia is a premalignant lesion of the breast (relative risk ~ 4.0). Here, we asked if Ki67 expression could stratify risk in women with atypia. Ki67 expression was assessed immunohistochemically by digital image analysis in archival sections from 192 women with atypia diagnosed at the Mayo Clinic 1/1/67–12/31/91. Risk factor and follow-up data were obtained via study questionnaire and medical records. Observed breast cancer events were compared to population expected rates (Iowa SEER) using standardized incidence ratios (SIRs). We examined two endpoints: risk of breast cancer within 10 years and after 10 years of atypia biopsy. Thirty-two (16.7%) of the 192 women developed breast cancer over a median of 14.6 years. Thirty percent (58) of the atypias had ≥2% cells staining for Ki67. In these women, the risk of breast cancer within 10 years after atypia was increased (SIR 4.42 [2.21–8.84]) but not in those with <2% staining. Specifically, the cumulative incidence for breast cancer at 10 years was 14% in the high Ki67 vs. 3% in the low Ki67 group. Conversely, after 10 years, risk in the low Ki67 group rose significantly (SIR 5.69 [3.63–8.92]) vs. no further increased risk in the high Ki67 group (SIR 0.78 [0.11–5.55]). Ki67 appears to be a time-varying biomarker of risk of breast cancer in women with atypical hyperplasia.
KeywordsAtypical hyperplasia Breast cancer risk Ki-67 Immunohistochemistry
This work was supported by NCI RO1 grant CA132879, Mayo Clinic Breast Cancer SPORE CA116201, and the Martha and Bruce Atwater Foundation. We thank Linda Murphy for immunostaining; Teresa Allers, Jo Johnson, Mary Campion, Melanie Kasner, and Romayne Thompson for data collection; Joel Worra for database development; Ann Harris and the Survey Research Center for patient follow-up; and Vicki Shea for assistance with manuscript preparation.
- 1.Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2007) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237CrossRefGoogle Scholar
- 2.Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC (2007) Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 25(19):2671–2677CrossRefPubMedGoogle Scholar
- 27.Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24(19):3019–3025CrossRefPubMedGoogle Scholar
- 28.Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orland L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M (2008) Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER—and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99(10):1564–1571CrossRefPubMedGoogle Scholar
- 30.Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90(18):1371–1388CrossRefPubMedGoogle Scholar
- 38.Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ (2006) Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 48(3):258–267CrossRefPubMedGoogle Scholar